tirzepatide common name PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: Tirzepatide shelf life: how long

doi: 10.7759/cureus.25946, 12

Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment

And scaled it with a system

Topical diphenylcyclopropenone or diphencyprone in various concentrations (0.0001% to 10%) in solution or cream may be useful for small cutaneous melanoma metastases